Feasibility Study of Neoadjuvant Olaparib for Frontline BRCA Mutant Ovarian Cancer

Authors

Victoria Michael, McGovern Medical SchoolFollow
Shannon N. Westin, The University of Texas MD Anderson Cancer Center
Michaela Onstad-Grinsfelder, The University of Texas MD Anderson Cancer Center
Larissa A. Meyer, The University of Texas MD Anderson Cancer Center
Nicole Fleming, The University of Texas MD Anderson Cancer Center
Yin Yuan, The University of Texas MD Anderson Cancer Center

Files

DOI

https://doi.org/10.52519/00018

Keywords

Olaparib, Neoadjuvant, BRCA Mutation

Program Affiliation

Partnership for Careers in Cancer Science and Medicine

Recommended Citation

Michael, Victoria; Westin, Shannon N.; Onstad-Grinsfelder, Michaela; Meyer, Larissa A.; Fleming, Nicole; and Yuan, Yin, "Feasibility Study of Neoadjuvant Olaparib for Frontline BRCA Mutant Ovarian Cancer" (2022). Summer Experience 2022. 93.
doi:https://doi.org/10.52519/00018